Acute promyelocytic leukemia, as a distinct subtype of AML, accounts for approximately 10% to 15% of confirmed AML cases.[1] The combination of ATRA and ATO, which acts by targeting the PML-RARα fusion protein and thereby inducing promyelocyte differentiation and apoptosis, has become the standard treatment for APL with outstanding therapeutic outcomes. Here, RARA is linked to acute myeloid leukemia.